Synthetic Drug Control Act of 2015
Introduced on 9-17-15 by Charles Dent [R-PA-15] and referred to Committee on Energy and Commerce, and Judiciary. Cosponsors were James Himes [D-CT-4], Patrick Meehan [R-PA-7], Robert Dold [R-IL-10], Patrick Tiberi [R-OH-12], Ryan Costello [R-PA-6], Richard Hanna [R-NY-22], Glenn Thompson [R-PA-5], Harold Rogers [R-KY-5], Tim Murphy [R-PA-18], Lou Barletta [R-PA-11], Eleanor Norton [D-DC-At Large], Leonard Lance [R-NJ-7], Barbara Comstock [R-VA-10], John Katko [R-NY-24], Ileana Ros-Lehtinen [R-FL-27], David Jolly [R-FL-13], Rodney Davis [R-IL-13], Henry Cuellar [D-TX-28], Brett Guthrie [R-KY-2], Mac Thornberry [R-TX-13], Mike Bishop [R-MI-8], Peter King [R-NY-2], Rick Allen [R-GA-12], Pedro Pierluisi [D-PR-At Large], Marcy Kaptur [D-OH-9], and Scott Peters [D-CA-52].
Purpose: To amend the Controlled Substances Act to clarify how controlled substance analogues are to be regulated,
SEC. 2. Controlled substance analogues.
Broadens the definition of a controlled substance analogue and increases limitations.
SEC. 3. Treatment of certain designer drugs as schedule I controlled substances.
Provides extensive lists of compounds considered to be controlled substance analogues, using their chemical names.